| scholarly article | Q13442814 |
| P50 | author | David E. J. Jones | Q89209099 |
| P2093 | author name string | Amardeep Khanna | |
| P2860 | cites work | Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis | Q27023986 |
| The enzymes, regulation, and genetics of bile acid synthesis | Q28204726 | ||
| Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades | Q28240299 | ||
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| Ursodeoxycholic acid-dependent activation of the glucocorticoid receptor | Q28327797 | ||
| A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis | Q28569818 | ||
| Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening | Q30277347 | ||
| Up-regulation of microRNA 506 leads to decreased Cl-/HCO3- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. | Q30522942 | ||
| Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study | Q33419647 | ||
| Varices in early histological stage primary biliary cirrhosis | Q34139088 | ||
| The immunobiology and pathophysiology of primary biliary cirrhosis | Q34324185 | ||
| Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. | Q34330984 | ||
| Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. | Q34453425 | ||
| Plasmaphoresis and plasma exchange in the treatment of hyperlipaemia and xanthomatous neuropathy in patients with primary biliary cirrhosis | Q34475584 | ||
| Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials | Q34550505 | ||
| Pathogenesis of primary biliary cirrhosis | Q34653850 | ||
| Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions | Q34764961 | ||
| Natural history of primary biliary cirrhosis. | Q35573903 | ||
| Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. | Q35594405 | ||
| Opioid peptides and primary biliary cirrhosis | Q35706319 | ||
| Klotho coreceptors inhibit signaling by paracrine fibroblast growth factor 8 subfamily ligands | Q35943927 | ||
| Management of Pruritus in Primary Biliary Cholangitis: A Narrative Review | Q36291016 | ||
| Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis | Q36495172 | ||
| Randomized controlled trial of cholestyramine and hydrotalcite to eliminate bile for capsule endoscopy | Q36755441 | ||
| Interpreting serological tests in diagnosing autoimmune liver diseases | Q36829645 | ||
| Pleiotropic roles of bile acids in metabolism | Q36843966 | ||
| Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: case reports | Q37140216 | ||
| Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis | Q37760788 | ||
| Gabapentin for pruritus in palliative care | Q38007412 | ||
| Beyond intestinal soap--bile acids in metabolic control. | Q38211374 | ||
| Mechanisms of tissue injury in autoimmune liver diseases | Q38235918 | ||
| Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. | Q38300264 | ||
| Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. | Q38413146 | ||
| 'Out-patient' albumin dialysis for cholestatic patients with intractable pruritus | Q38460458 | ||
| Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. | Q38467441 | ||
| Management of cholestatic disease in 2017. | Q38774857 | ||
| Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial | Q39344418 | ||
| Treatment of pruritus of primary biliary cirrhosis with rifampin | Q39511303 | ||
| Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial | Q39533520 | ||
| Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score | Q39584105 | ||
| Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. | Q39595436 | ||
| The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. | Q40681087 | ||
| A controlled trial of naloxone infusions for the pruritus of chronic cholestasis | Q41142015 | ||
| Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. Repression of IFN-gamma-induced MHC class II gene expression via a glucocorticoid receptor-dependent pathway | Q41228648 | ||
| Severe coagulopathy caused by rifampicin in patients with primary sclerosing cholangitis and refractory pruritus | Q43230366 | ||
| Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid | Q43483632 | ||
| Functional modulation of the glucocorticoid receptor and suppression of NF-kappaB-dependent transcription by ursodeoxycholic acid | Q43750966 | ||
| Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid | Q43893454 | ||
| FXR and ABCG5/ABCG8 as determinants of cholesterol gallstone formation from quantitative trait locus mapping in mice | Q44569556 | ||
| Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. | Q44573504 | ||
| Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis | Q44700997 | ||
| Combined loss of orphan receptors PXR and CAR heightens sensitivity to toxic bile acids in mice | Q45201689 | ||
| The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis | Q45247238 | ||
| Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis | Q46049458 | ||
| Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid | Q46126105 | ||
| Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis | Q46408092 | ||
| Pilot study of peripheral muscle function in primary biliary cirrhosis: potential implications for fatigue pathogenesis | Q46436991 | ||
| A key role for autoreactive B cells in the breakdown of T-cell tolerance to pyruvate dehydrogenase complex in the mouse | Q46437739 | ||
| Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid | Q46489034 | ||
| Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis | Q46568191 | ||
| Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans | Q46954707 | ||
| Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. | Q47440077 | ||
| Glucocorticoid receptor-dependent immunomodulatory effect of ursodeoxycholic acid on liver lymphocytes in mice | Q47979795 | ||
| The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis | Q49110706 | ||
| Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man. | Q51558596 | ||
| A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis | Q51586165 | ||
| The incidence of pruritus after epidural morphine. | Q51748346 | ||
| Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. | Q52541251 | ||
| Plasmapheresis exerts a long-lasting antipruritic effect in severe cholestatic itch. | Q52994563 | ||
| Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis'. | Q53339911 | ||
| Primary biliary cirrhosis | Q56428273 | ||
| Primary biliary cirrhosis | Q56854243 | ||
| Cholestasis-induced pruritus treated with ultraviolet B phototherapy: an observational case series study | Q56931599 | ||
| The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study | Q57139260 | ||
| Primary biliary cirrhosis | Q57141930 | ||
| Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis | Q57205203 | ||
| EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis | Q59384401 | ||
| Sertraline as a first-line treatment for cholestatic pruritus | Q61480066 | ||
| Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis | Q71949350 | ||
| Ursodeoxycholic acid in the treatment of primary biliary cirrhosis | Q72401649 | ||
| Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes | Q73486365 | ||
| Assessment of biliary bicarbonate secretion in humans by positron emission tomography | Q77921993 | ||
| Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study | Q78554315 | ||
| Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials | Q80215317 | ||
| Nasobiliary drainage for cholestatic pruritus | Q83182724 | ||
| Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome | Q84441124 | ||
| [Obeticholic acid in primary biliary cholangitis : PBC OCA international study of efficacy (POISE)] | Q89950561 | ||
| Elafibranor for the treatment of NAFLD: One pill, two molecular targets and multiple effects in a complex phenotype | Q95384841 | ||
| P433 | issue | 10 | |
| P921 | main subject | ascending cholangitis | Q603644 |
| P304 | page(s) | 791-803 | |
| P577 | publication date | 2017-09-07 | |
| P1433 | published in | Therapeutic Advances in Gastroenterology | Q21042423 |
| P1476 | title | Novel strategies and therapeutic options for the management of primary biliary cholangitis | |
| P478 | volume | 10 |
| Q64230889 | Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel | cites work | P2860 |
Search more.